PRESCIENT THERAPEUTICS LIMITED The Company Announcements Platform ASX Limited
By E-lodgement
Investors have subscribed for $1,201,500 in new shares, with the price per share to be based on a 20% discount to the 5 day volume weighted average price (VWAP) before the issue date of 23 November 2015.
A final price will be announced on the date of issue of the SPP shares.
PTX advises that the Company is only permitted to accept a maximum of 30% of its current issued capital. In the event that a scale back is required, applications for new shares will be scaled back proportionately.
Further details on this scale back will be provided on the issue date.
The Board wishes to thank all shareholders for their continued support and level of interest shown through this SPP.
Executive Director Monsoon Communications
+61 406 671 515 +61 (0) 3 9620 3333
PTX is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.
Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as AKT, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukaemia. This highly promising compound is now the focus of two current clinical trials. The first is a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. A Phase 1b/2 trial of the compound in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at Florida's H. Lee Moffitt Cancer Center. These
Prescient Therapeutics Limited
Level 4, 100 Albert Road, South Melbourne, VIC 3205
Phone: +61 3 9692 7222 Fax: +61 3 9077 9233
ABN: 56 006 569 106 ACN: 006 569 106
www.prescienttherapeutics.com
trials are funded in part by grants from the U.S. National Cancer Institute. In addition, PTX is planning a Phase 1b/2 trial evaluating PTX-200 as a new therapy for acute myeloid leukemia.
PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors.
PTX has licensed access to its Co-X-Gene™ platform technology to French biotechnology company Transgene for use in two immunotherapeutic products.
Prescient Therapeutics Limited
Level 4, 100 Albert Road, South Melbourne, VIC 3205
Phone: +61 3 9692 7222 Fax: +61 3 9077 9233
ABN: 56 006 569 106 ACN: 006 569 106
www.prescienttherapeutics.com
|
distributed by
|
